SCHEMBL4265086

SCHEMBL4265086

O=C(Nc1ccc(Oc2ccccc2)cc1)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.69
MAPK14 Q16539 2/20 0.64
BRAF P15056 1/20 0.64
KDR P35968 1/20 0.64
TNNI3K Q59H18 1/20 0.64
FNTA P49354 1/20 0.60
FNTB P49356 1/20 0.60
RAB9A P51151 3/20 0.59
PGR P06401 1/20 0.59
NPC1 O15118 1/20 0.59
CA12 O43570 2/20 0.58
CA1 P00915 2/20 0.58
CA2 P00918 2/20 0.58
CA9 Q16790 2/20 0.58
MEN1 O00255 2/20 0.58
MAPT P10636 2/20 0.58
HTT P42858 2/20 0.58
KMT2A Q03164 2/20 0.58
FAAH O00519 1/20 0.57
PDK1 Q15118 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4260471 0.90 KDR (0.67) EPHX2MAPK14BRAFKDRTNNI3K
SCHEMBL4259959 0.88 EPHX2 (0.76) EPHX2MAPK14BRAFKDRTNNI3K
SCHEMBL20941788 0.88 FNTA (0.67) EPHX2MAPK14FNTAFNTBRAB9A
SCHEMBL4548071 0.87 EPHX2 (0.85) EPHX2RAB9ANPC1CA12CA1
SCHEMBL20942376 0.87 FNTA (0.59) EPHX2MAPK14BRAFKDRTNNI3K
SCHEMBL20941552 0.87 FNTA (0.59) EPHX2MAPK14BRAFKDRTNNI3K
SCHEMBL4256156 0.87 EPHX2 (0.61) EPHX2MAPK14BRAFKDRTNNI3K
SCHEMBL30053559 0.87 CA12 (0.73) EPHX2RAB9APGRNPC1CA12
SCHEMBL21295380 0.85 CA12 (0.71) EPHX2RAB9APGRCA12CA1
SCHEMBL4261927 0.85 EPHX2 (0.69) EPHX2MAPK14BRAFKDRTNNI3K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023731-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2009-01-22 US claimed
US-20090023731-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2009-01-22 US disclosed
US-20090023731-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2009-01-22 US disclosed
US-20090023731-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2009-01-22 US disclosed
WO-2008116145-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-09-25 WO disclosed
WO-2008116145-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023731-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 EPHX2 2/4885MAPK14 3113/4885BRAF 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.